For this year Biogen's revenue will be around 13,74 billion USD. This is according to the average of the analysts' estimates. This is slightly more than 2017's revenue of 13,45 billion USD.
The analysts expect for 2018 a net profit of 5,68 billion USD. The majority of the analysts expects for this year a profit per share of 28,91 USD. So the price/earnings-ratio equals 7,91.
Analysts don't expect the company to pay a dividend. The average dividend yield of the biotech companies equals a low 0,5 percent.
Biogen's market capitalization is based on the number of outstanding shares around 48,39 billion USD. The Biogen stock was the past 12 months quite unstable. Since last April the stock is 12 percent lower. This year the stock price moved between 216 and 389 dollar. Since 2008 the stock price is almost 440 percent higher.
ValueSpectrum.com News Wire & Equity Research: +31 084-0032-842
Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.